Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

NCT06943521 is registered in ClinicalTrials.gov with Tanabe Pharma America, Inc. as lead sponsor.

NCT NCT06943521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06943521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam
Lead sponsor
Tanabe Pharma America, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 18, 2025
Completion date
August 31, 2028
Enrollment
27 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma (hnscc), neuroendocrine carcinoma (nec), neuroendocrine tumor (net), non-small cell lung cancer (nsclc), nuclear protein in testis (nut) carcinoma, ovarian cancer, pancreatic ductal adenocarcinoma (pdac), prostate cancer, soft tissue sarcoma, urothelial carcinoma